Skip to main content
Pipeline

Pipeline Programs

EB-003

Program Status and Projected Milestones

Prescription Model

Highlights

  • Moderate dose
  • Prescription model
  • Taken regularly
  • Minimal side effects and reduced hallucinations
  • Available to a large patient population

Enveric is advancing its EB-003, expected to offer a first-in-class, new approach to the treatment of difficult-to-address anxiety, depression and other disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.

Synopsis of Target Benefits

  • Reduced hallucination profile
  • Improved cardiac safety
  • Orally bioavailable, chronic administration
  • Treatment in clinic not required
  • Drug intended to be prescribed for regular maintenance and taken at times and in settings more convenient to patient